Table 1.

Several clinical trials are underway to test the efficacy of RAS modifying agents in COVID-19 positive patients

Study title	Status
Recombinant bacterial ACE2 receptors -like enzyme of B38-CAP could be promising COVID-19 infection- and lung injury preventing drug better than recombinant human ACE2	Not yet recruiting
Combination of recombinant bacterial ACE2 receptors like enzyme of B38-CAP and isotretinoin coul be promising Covid 19 infection and lung injury preventing drug better than recombinant human ACE	Not yet recruiting
Impact of Angiotensin II Receptor Blockers treatment in patients with COVID-19	Recruiting
Switch of Renin-Angiotensin system inhibitors in patients with Covid-19	Recruiting
Renin angiootensin aldosterone system inhibitors,hypertension and Covid-19	Not yet recruiting
Telmisartan for treatment of Covid-19 patients	Completed
Treatment of angiotensin peptide (1–7) for Covid-19	Recruiting
Telmisartan in respiratory failure due to COVID-19	Recruiting
ACE Inhibitors, Angiotensin II Type-I receptor blockers and severity of COVID-19	Completed